About Sammy Elmariah, MD, MPH

Dr. Sammy Elmariah graduated from the University of Pennsylvania School of Medicine and completed his internal medicine residency training at the Hospital of the University of Pennsylvania. He subsequently served as Chief Medical Resident at Lankenau Hospital. Dr. Elmariah completed his fellowship in cardiovascular medicine at the Mount Sinai Hospital in New York where he also served as Chief Fellow. While a fellow, he also completed a Masters in Public Health at the Harvard School of Public Health. Dr. Elmariah completed further fellowship training in interventional cardiology and structural heart disease at the Massachusetts General Hospital.

Currently, Dr. Elmariah is an interventional cardiologist and structural heart disease specialist at the Massachusetts General Hospital and Assistant Professor of Medicine at the Harvard Medical School. In addition, he serves as the Director of Interventional Structural Heart Disease at the Boston VA Healthcare System. He is also the Associate Director of Trial Design at the Harvard Clinical Research Institute.

His clinical interest is in the management of valvular heart disease, coronary artery disease, and adult congenital heart disease. He performs transcatheter valve replacement, percutaneous coronary interventions (stents), and transcatheter closure of patent foramen ovale (PFO) and atrial septal defects (ASD).

Dr. Elmariah has a specific research interest in valvular heart disease. In addition to ongoing clinical investigation of valve calcification and the progression of aortic stenosis, Dr. Elmariah is evaluating the impact of transcatheter aortic valve replacement on myocardial metabolism and myocardial remodeling. Dr. Elmariah is an MGH Heart Center Hassenfeld Research Scholar and has been awarded the Jeremiah Stamler Distinguished Young Investigator Award and an American College of Cardiology Young Investigator Award.

Clinical Interests:



Interventional Cardiology Associates
55 Fruit Street
Boston, MA 02114
Phone: 617-726-6120
Fax: 617-726-9839

Medical Education

  • MPH, Harvard T. H Chan School of Public Health
  • MD, University of Pennsylvania Medical Ctr.
  • MD, University of Pennsylvania School of Medicine
  • Residency, Hospital of the University of Pennslvania
  • Residency, Hospital of the University of Pennsylvania
  • Residency, Lankenau Hospital
  • Fellowship, Massachusetts General Hospital
  • Fellowship, Mount Sinai Hospital Medical Center
  • Fellowship, Mount Sinai Medical Center

American Board Certifications

  • Interventional Cardiology, American Board of Internal Medicine
  • Cardiovascular Disease, American Board of Internal Medicine
  • Cardiovascular Disease, American Board of Internal Medicine

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Dr. Elmariah's research focuses on the prediction and optimization of clinical outcomes of patients with aortic stenosis and after transcatheter aortic valve replacement. Aortic valve stenosis is a disorder predominantly affecting the elderly and characterized by severe narrowing of the aortic valve, the doorway through which blood exits the heart. Aortic stenosis ultimately leads to heart failure and death. Surgical or transcatheter replacement of the valve cures the valve obstruction, but valve replacement is routinely reserved until compensatory mechanisms within the heart have failed. For many patients, this point is too late. Despite valve replacement, damage to the heart muscle may be permanent, resulting in persistent symptoms and increased risk for death. Methods capable of identifying early stages of irreversible heart injury due to aortic valve stenosis are needed in order to help optimize the timing of surgery.

The long-term goal of Dr. Elmariah's work is to identify novel blood markers using novel proteomic and metabolomic profiling techniques that predict heart recovery after valve surgery. Dr. Elmariah anticipates that such measures will help physicians optimize the timing of aortic valve replacement in order to maximize the likelihood that surgery will improve their patients’ symptoms and prolong their lives. Additionally, the type of heart injury that occurs with aortic stenosis also occurs with high blood pressure, diabetes, and several other diseases. Findings from his research have the potential to improve the quality of care for many of these diseases as well.


  • View my most recent publications at PubMed

    Select Publications:

    • Elmariah S, Farrell LA, Daher M, et al. Metabolite profiles predict acute kidney injury and mortality in patients undergoing transcatheter aortic valve replacement. J Am Heart Assoc. 2016;5(3). 
    • Mauri L, Elmariah S, Yeh RW, et al. Causes of late mortality with dual antiplatelet therapy after coronary stents. Eur Heart J. 2016;37(4):378-85.
    • Feldman T, Kar S, Elmariah S, et al. Randomized comparison of percutaneous repair and surgery for mitral regurgitation: final 5-year results of the EVEREST II study. J Am Coll Cardiol. 2015;66(25):2844-54.
    • Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet. 2015;385(9970):792-8.
    • Passeri JJ, Elmariah S, Xu K, et al. Transcatheter aortic valve replacement and standard therapy in inoperable patients with aortic stenosis and low ejection fraction. 2014;101(6):463-71.
    • Elmariah S, Furlan AJ, Reisman M, et al. Predictors of recurrent events in patients with cryptogenic stroke and patent foramen ovale within the CLOSURE I trial. JACC Cardiovasc Interv. 2014;7:913-20.
    • Elmariah S, Palacios IF, McAndrew T, et al. Outcomes of transcatheter and surgical aortic valve replacement in high-risk patients with aortic stenosis and left ventricular dysfunction: Results from the PARTNER trial (Cohort A). Circ Cardiovasc Interv. 2013;6(6):604-14.